Tobacco Cessation:
Essential Steps for Success
Dr. Janie Heath, Georgetown University
Dr. Jeannette Andrews, Medical College of Georgia Dr. Claudia Barone, University of Arkansas Medical Sciences
Objectives
Identify the importance of integrating tobacco cessation in DAILY practice Identify key strategies / approaches for integrating tobacco cessation in DAILY practice Identify essential resources for integrating tobacco cessation in DAILY practice
Why Make Tobacco Cessation a Standard for Practice?
QUALITY OUTCOMES = PAYMENT and HEALTH HEIDIS says to do it!
JCAHO says to do it!
The Surgeon General says to do it! The wife says to do it! [Link]
TRENDS in ADULT SMOKING, by SEXU.S., 19552004
Trends in cigarette current smoking among persons aged 18 or older
60 50 40
Male
20.9% of adults are current smokers
23.4% 18.5%
Percent
30 20 10 0
1955 1959 1963 1967 1971 1975 1979 1983 1987 1991 1995 1999 2003
Female
44.5 Million Adults are Addicted to Cigarettes
Year
The BAD News: < 36% News: Receive70% Information The GOOD want on to HOW quit to quit
Graph provided by the Centers for Disease Control and Prevention. 1955 Current Population Survey; 19652001 NHIS. Estimates since 1992 include some-day smoking.
STATE-SPECIFIC PREVALENCE of SMOKING among ADULTS, 2004
California 14.8% Kentucky 27.6%
Nevada 23.2% Utah 10.5% Ark 25.7% VA 20.9% GA 20.1%
Centers for Disease Control and Prevention. (2005). MMWR 54:11241127.
PREVALENCE of ADULT SMOKING, by RACE/ETHNICITYU.S., 2004
33.4% American Indian/Alaska Native 22.2% White, non-Hispanic 20.2% Black, non-Hispanic 15.0% Hispanic
11.3% Asian
0% 10% 20% 30% 40% 50%
Centers for Disease Control and Prevention. (2005). MMWR 54:11211124.
Prevalence and Harm of SMOKING during PREGNANCY
Miscarriage Stillbirth
Preterm delivery
Low birth weight
BABY ALERT: 27% OF Tobacco Dependent WOMEN Continue to SMOKE THROUGHOUT PREGNANCY
PREVALENCE of ADULT SMOKING, by EDUCATIONU.S., 2004
26.2% No high school diploma 39.6% GED diploma 24.0% High school graduate 22.2% Some college 11.7% Undergraduate degree 8.0% Graduate degree
0% 10% 20% 30% 40% 50%
Centers for Disease Control and Prevention. (2005). MMWR 54:11211124.
Annual Causes of Death from Smoking Compared to Other PREVENTABLE Causes
440 400 360 320 280 240 200 160 120 80 40 0
Number of Deaths (thousands)
430
81 17
A ID S oh ol
41
19
e
14
ce d
30
ic l
ic id
ic id
eh
In du
A lc
Sources: (AIDS) HIV/AIDS Surveillance Report, 1998; (Alcohol) McGinnis MJ, Foege WH. Review: Actual Causes of Death in the United [Link] 1993;270:2207-12; (Motor vehicle) National Highway Transportation Safety Administration, 1998; (Homicide, Suicide) NCHS, vital statistics, 1997; (Drug Induced) NCHS, vital statistics, 1996; (Smoking) SAMMEC, 1995
H om
Su
ot o
D ru g
Sm
rV
ok in
ANNUAL U.S. DEATHS ATTRIBUTABLE to SMOKING, 19972001
Percentage of all smokingattributable deaths*
Cardiovascular diseases Lung cancer Respiratory diseases Second-hand smoke Cancers other than lung Other
137,979 123,836 101,454 38,112 34,693 1,828
32% 28% 23% 9% 8% <1%
TOTAL: 437,902 deaths annually
Centers for Disease Control and Prevention. (2005). MMWR 54:625628.
FINANCIAL IMPACT of SMOKING
Buying cigarettes every day for 50 years @ $4.12 per pack Money banked monthly, earning 1.5% interest
$331,467
$220,978
Packs per day
$110,489
0 100 200 300 400
Hundreds of thousands of dollars lost
COMPOUNDS in TOBACCO SMOKE
An estimated 4,800 compounds in tobacco smoke
Gases (~500 isolated)
Particles (~3,500 isolated)
Carbon monoxide Hydrogen cyanide Ammonia Benzene Formaldehyde
Nicotine Nitrosamines Lead Cadmium Polonium-210
Marketing Strategy: Light and Ultra-Light Cigarettes
The difference between Marlboro and Marlboro Lights
15mg tar, 1.1 mg nicotine
10mg tar, 0.8 mg nicotine
an extra row of ventilation holes
Image courtesy of Mayo Clinic Nicotine Dependence Center - Research Program / Dr. Richard D. Hurt
The Marlboro and Marlboro Lights logos are registered trademarks of Philip Morris USA.
The Safer Cigarette NOT!
Unveiling the SMOKING gun about Safe Cigarettes!
Other Tobacco Products
Chewing tobacco
Looseleaf Plug Twist
Snuff
Moist Dry
The Copenhagen and Skoal logos are registered trademarks of U.S. Smokeless Tobacco Company, and Red Man is a registered trademark of Swedish Match.
BENEFICIAL EFFECTS of QUITTING: PULMONARY EFFECTS
AT ANY AGE, there are benefits of quitting.
FEV1 (% of value at age 25)
100
Heres how to do it!
Breaking the NICOTINE DEPENDENCE Cycle
Smoked regularly and susceptible to effects of smoke Disability
Never smoked or not susceptible to smoke
75 A COMPREHENSIVE APPROACH = A Successful Framework for Quitting Stopped smoking at 45 (mild COPD)
50
25
The BEHAVIOR
The EMOTIONAL
The PHYSICAL
Stopped smoking at 65 (severe COPD)
Death 0 25
Automatic learned behavior with cigarettes
50
Role of cigarettes in life pleasure, stress, social
75
Age (years)
Physical addiction of cravings & withdrawals
Adapted from Legacys GSD&M Presentation 12/5/03 COPD = chronic obstructive pulmonary disease
Reprinted with permission. Fletcher & Peto. (1977). BMJ 1(6077):16451648.
Breaking the NICOTINE DEPENDENCE Cycle
A COMPREHENSIVE APPROACH = A Successful Framework for Quitting
The BEHAVIOR
The EMOTIONAL
The PHYSICAL
Automatic learned behavior with cigarettes
Role of cigarettes in life pleasure, stress, social
Physical addiction of cravings & withdrawals
Adapted from Legacys GSD&M Presentation 12/5/03
DOPAMINE REWARD PATHWAY
Prefrontal cortex
Dopamine release
Nucleus accumbens Ventral tegmental area
Stimulation of nicotine receptors Nicotine enters brain
NICOTINE BEHAVIORAL EFFECTS: Do the Math!
An individual smokes 1 pack per day x 20 yrs 20 cigarettes / pack 10 puffs / cigarette = ?? puffs / day
200 HITS of THATs ____ NICOTINE per DAY
Now Multiply that # by days / year 73,000 THEN multiply that number by years smoking! 1.4 million
YIKES! No wonder it is SO difficult to QUIT
NEUROCHEMICAL and RELATED EFFECTS of NICOTINE
N Dopamine I
Pleasure, reward Arousal, appetite suppression Arousal, cognitive enhancement Learning, memory enhancement Mood modulation, appetite suppression Reduction of anxiety and tension Reduction of anxiety and tension
Norepinephrine
Acetylcholine Glutamate Serotonin
C
O T I E
N -Endorphin
GABA
Benowitz. (1999). Nicotine Tob Res 1(Suppl):S159S163.
NICOTINE PHARMACODYNAMICS: WITHDRAWAL EFFECTS
Depression Insomnia Irritability/frustration/anger Anxiety Difficulty concentrating Restlessness Increased appetite/weight gain Decreased heart rate Cravings*
American Psychiatric Association. (1994). DSM-IV. Hughes et al. (1991). Arch Gen Psychiatry 48:5259. Hughes & Hatsukami. (1998). Tob Control 7:9293.
Most symptoms peak 2448 hr after quitting and subside within 24 weeks.
* Not considered a withdrawal symptom by DSM-IV criteria.
ASSESSING NICOTINE DEPENDENCE
How soon after you wake up do you smoke your first cigarette
Do you find it difficult to refrain from smoking in restricted areas Which cigarette do you hate to give up most How many cigarettes do you smoke per day Do you smoke more frequently during the first hours after waking Do you smoke if you are so ill that you are in bed most of the day
Fagerstrm Test for Nicotine Dependence (FTND)
Scores range from 0 to 10; a score of greater than 5 indicates substantial dependence
The 5 As
ASK
ADVISE ASSESS ASSIST ARRANGE
HANDOUT
Fiore et al. (2000). Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: USDHHS, PHS.
If LIMITED Time Provide BRIEF COUNSELING: ASK, ADVISE, ASSESS, REFER
Brief interventions have been shown to be effective In the absence of time or expertise:
Ask, advise, assess, and refer to other resources, such as local programs or the toll-free quitline 1-800-QUIT-NOW
This brief intervention can be achieved in 30 seconds.
FIVE STAGES THAT DESCRIBE a PERSONS READINESS to CHANGE
STAGE 1: Precontemplation = No way STAGE 2: Contemplation = Possibly ready STAGE 3: Preparation = Definitely ready STAGE 4: Action = Doing it now STAGE 5: Maintenance = Changed already
METHODS for INCREASING MOTIVATIONFIVE Rs
FOR INDIVIDUALS NOT READY TO QUIT YET: Tailor messages
with Motivational Interviewing Techniques
RELEVANCE RISKS REWARDS
ROADBLOCKS
REPETITION
Fiore et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: USDHHS, PHS, 2000.
STRATEGIES for Successful Tobacco Cessation
PRAISE the individuals readiness Facilitate the quitting process ESTABLISH THE PLAN
Set a quit date!
Help Build Tools for a QUIT Kit to Success
Emotional - Cognitive Tools Behavioral - Tools Physical - Biological Tools
Cognitive STRATEGIES
#1 Individualize the plan #2 Assess MOTIVATION to quit (0-10) #3 Assess CONFIDENCE to quit (0-10) #4 Assess triggers for tobacco use Routines/situations associated with tobacco use Tobacco Log
#5 Assess social support
#6 Advise a daily affirmation slay the dragon /
nicotine demon- I can do this
Behavioral STRATEGIES
#7 Discuss how the to change routine Breaking QUITTING isNICOTINE hard to do. Non-food / healthy items instead of cigarettes DEPENDENCE Cycle Tea instead of coffee / Exercise instead of smoking ALL cycles must be addressed for SUCCESS! A COMPREHENSIVE APPROACH = A Successful Framework for Quitting #8 Discuss coping skills for situational and/or emotional triggers
The The The Withdrawal concerns the 4 Ds PHYSICAL BEHAVIORThe EMOTIONAL The The
Weight gain concerns
Relapse concernsEMOTIONAL BEHAVIOR
PHYSICAL
#9 Discuss how to prepare for QUIT day
Home Car - Office Automatic learned Role of cigarettes in life Treats for SELF behavior with cigarettes pleasure, stress, social
Physical addiction of cravings & withdrawals
#10 Discuss pharmacotherapy options
Adapted from Legacys GSD&M Presentation 12/5/03
Breaking the NICOTINE DEPENDENCE Cycle
A COMPREHENSIVE APPROACH = A Successful Framework for Quitting
The BEHAVIOR
The EMOTIONAL
The PHYSICAL
Automatic learned behavior with cigarettes
Role of cigarettes in life pleasure, stress, social
Physical addiction of cravings & withdrawals
Adapted from Legacys GSD&M Presentation 12/5/03
Nicotine Replacement Therapy (NRT): RATIONALE for USE
Reduces physical withdrawal from nicotine Allows patient to focus on behavioral and psychological aspects of tobacco cessation It is NOT substituting ONE negative health behavior for another IMPROVES SUCCESS RATES!
LONG-TERM (6 month) QUIT RATES for AVAILABLE CESSATION MEDICATIONS
30 25
Active drug Placebo
19.5 16.4
23.9 20.0 17.1
Percent quit
20 15
14.6 11.5 11.8 8.6 8.8 9.1 10.2
10 5 0 Nicotine gum
Nicotine patch
Nicotine lozenge
Nicotine nasal spray
Nicotine inhaler
Bupropion
Data adapted from Silagy et al. (2004). Cochrane Database Syst Rev and Hughes et al., (2004). Cochrane Database Syst Rev.
FDA APPROVALS: SMOKING CESSATION
Rx transdermal nicotine patch
2002 1997 1996
OTC nicotine lozenge
Rx nicotine gum
1991
Rx nicotine inhaler; Rx bupropion SR
OTC nicotine gum & patch; Rx nicotine nasal spray
1984
NICOTINE ABSORPTION
Absorption is pH dependent
In acidic media
Ionized poorly absorbed across membranes Nonionized well absorbed across membranes
In alkaline media
At physiologic pH (7.37.5), nicotine is readily absorbed.
PLASMA NICOTINE CONCENTRATIONS for NICOTINECONTAINING PRODUCTS
25
Cigarette
Cigarette
20
Moist snuff
Plasma nicotine (mcg/l)
Moist snuff
Nasal spray
15
Inhaler
10
Lozenge (2mg)
Gum (2mg)
5
Patch
0 1/0/1900 0 1/10/1900 10 1/20/1900 20 1/30/1900 30 2/9/1900 40 2/19/1900 50 2/29/1900 60
Time (minutes)
NICOTINE GUM: Nicorette;
generic
(GlaxoSmithKline; Watson Labs)
Dose = 1 every 1-2 hrs;
No food/beverage 15 min
Max = 24 / day
prior - during or 15 min post
Available: 2 mg, 4 mg; regular, mint, orange NOT recommended if use dentures
NICOTINE GUM: CHEWING TECHNIQUE SUMMARY
Chew slowly Chew again when the taste or tingle fades
Stop chewing at first sign of peppery, minty, or citrus taste or tingle
Park
TRANSDERMAL NICOTINE PATCH
Dose = 1 patch every day (16 hrs or 24 hrs) Best if ROTATE patch different areas Preferred sites above the waist Avoid if acute / chronic skin condition If problems sticking apply TEGADERM dressing over patch May bathe/swim with patch Do NOT cut patch
NICOTINE LOZENGE Commit (GlaxoSmithKline)
Dose = 1every 1-2 hrs No food/beverage 15 min prior - during or 15 min post MAX = 20 per day Delivers ~25% more nicotine than equivalent gum dose Available: 2 mg, 4 mg Let dissolve 20-30 minutes; NO chewing/biting of product
NICOTINE NASAL SPRAY
Nicotrol NS (Pharmacia)
Dose = 1 dose (2 sprays per nostril) every hr MAX = 5 doses/hr OR 40 doses /day Each dose delivers -50 L spray = 0.5 mg nicotine per spray Rapidly absorbed across nasal mucosa --faster onset of action (1113 minutes) compared to the gum, patch, or inhaler
NICOTINE INHALER
Dose = 6- 16 cartridges / d
Nicotrol Inhaler (Pharmacia)
Puff as lighting a cigar/pipe best if puff for ~ 20 minutes
MAX = 16 cartridges / d
Delivers 4 mg nicotine vapor, which is absorbed across buccal mucosa - ~ 20 minutes of puffing = 1 cartridge
BUPROPION SR (ZYBAN)
(GlaxoSmithKline)
Non-nicotine agent Sustained release antidepressant
Dose = 150mg every a.m. x 3 days then 150mg twice a day IMPORTANT to start 2 wks prior to QUIT date
COMBINATION PHARMACOTHERAPY
Combination NRT
Long-acting formulation (patch)
Produces relatively constant levels of nicotine
PLUS Short-acting formulation (gum, lozenge, inhaler, nasal spray)
Allows for acute dose titration as needed for withdrawal symptoms
Bupropion SR + NRT
Reserve for patients unable to quit using monotherapy.
HELP on the HORIZON for SMOKING CESSATION
Georgetown Pilot RCT with Quest Cigarettes Phase II RCT with NicVAX (nicotine vaccine) Phase III RCT soon to be released Pfizers Varenicline / Champix QUITKEY for individuals who cannot or should not use NRT
COMPARATIVE DAILY COSTS of PHARMACOTHERAPY
Inhaler Gum Lozenge Bupropion SR Cigarettes (1 pack/day) Patch Nasal spray
$6.07 $5.81 $5.31 $5.24
$4.12
$3.93 $2.66
Cost per day, in U.S. dollars
Breaking the NICOTINE DEPENDENCE Cycle
A COMPREHENSIVE APPROACH = A Successful Framework for Quitting
The BEHAVIOR
The EMOTIONAL
The PHYSICAL
Automatic learned behavior with cigarettes
Role of cigarettes in life pleasure, stress, social
Physical addiction of cravings & withdrawals
Adapted from Legacys GSD&M Presentation 12/5/03
WHAT IF
a patient asks you about your use of tobacco?
The RESPONSIBILITY of HEALTH PROFESSIONALS
If we do not act decisively, a hundred years from now our grandchildren and their children will look back and seriously question how people claiming to be committed to public health and social justice allowed the tobacco epidemic to unfold unchecked.
DR. GRO HARLEM BRUNTLAND, FORMER DIRECTOR-GENERAL of the WHO
USDHHS. (2001). Women and Smoking: A Report of the Surgeon General. Washington, DC: PHS.
THANK YOU
Time for Questions & Interactive Cases
Workshop resources available at
[Link] [Link]
[Link]